Introduction
Transplantation of acute myeloid leukemia (AML) patients with grafts from related haploidentical donors has been shown to result in a potent graft-versus-leukemia eVect [1] [2] [3] . This eVect is mediated by NK cells which are activated because of the lack of interaction of inhibitory killer cell immunoglobulin-like receptors (KIRs) with their ligands HLA-Bw4 and HLA-C alleles. HLA-B molecules containing the serologically deWned HLA-Bw4 epitope determined by the amino acids at positions 77-83 interact with the inhibitory KIR3DL1 [4] . HLA-C antigens are the main ligands for the inhibitory KIRs, the speciWcity of the interaction being determined by a genetic polymorphism at positions 77 and 80. Group 2 HLA-C molecules (HLA-C2) which have Asp at position 77 and Lys at position 80 are bound by KIR2DL1, while group 1 HLA-C molecules (HLA-C1), which have Ser at position 77 and Asp at position 80, are bound by KIR2DL2 and KIR2DL3 [5] [6] [7] . However, conXicting results have been reported about the impact of the interactions of KIRs with their ligands HLABw4 and HLA-C alleles on the outcome of unrelated HLAmismatched hematopoietic stem cell transplants (HSCT) to leukemic patients [8] [9] [10] [11] [12] . Heterogeneity in the treatment procedures (conditioning regimen, graft composition and post-transplant immune suppression) and in the patient population (disease, risk category) may account for this discrepancy. However, the interpretation of these conXicting results is hampered by the scant and conXicting information about the level of HLA class I allele expression on leukemic cells, although this variable may aVect the activation of inhibitory KIRs.
To the best of our knowledge, HLA class I antigen expression has been investigated only on acute leukemic cells [13] [14] [15] [16] [17] and on B lineage chronic lymphoid leukemic (B-CLL) cells [18] . Staining of 49 newly diagnosed and 5 relapsed AML and 13 B-CLL samples with mAbs recognizing monomorphic determinants of HLA class I antigens did not detect defects in their expression in most of the samples [13, 14, 18] . However, we cannot exclude HLA class I allele downregulation or loss in these samples, since these defects are not detected by the mAb used. In addition, a low frequency of HLA-A allele downregulation has been recently described in leukemic samples analyzed at initial diagnosis with a few mAb which recognize HLA class I allospeciWcities and mAb which recognize monomorphic determinants [17] . In contrast, testing of nine AML and six B-ALL samples with allo-antisera detected downregulation of allospeciWcities in about 60% of the samples analyzed [14] . Furthermore, we have also found that 35% of HLA-A alleles and 38% of HLA-B alleles were downregulated in 32 leukemic patients in comparison to their autologous T cells [16] .
The paucity of information about HLA class I antigen expression on leukemic cells has a negative impact on our ability to optimize the selection of donor-recipient combinations for HSCT. Therefore in the present study taking advantage of a large panel of human mAb which recognize HLA class I allospeciWcities [19, 20] , we have analyzed the HLA-A, -B and -C allele expression level on leukemic cells. Furthermore, we have compared the HLA class I allele expression level on myeloid and lymphoid leukemic cells, since NK cells have been shown to inhibit the growth of AML cells, but to have no detectable eVect on that of acute lymphoid leukemic (ALL) cells [1, 2] . Last, to assess the functional signiWcance of HLA class I allele downregulation on leukemic cells, we have investigated the eVect of the HLA class I allele expression level on leukemic cells on their susceptibility to lysis by allogeneic NK cells.
Materials and methods

Patients and healthy volunteers
After informed consent, peripheral blood was collected with EDTA and citrate from 55 consecutive leukemic patients at the Department of Hemato-Oncology of the UZ Brussel and UZ Gent (Brussel and Gent, Belgium), respectively, between March 2003 and November 2006. The study protocol was approved by the Ethical Committee of the UZ Brussel.
The leukemic patients included 19 with AML (10 males and 9 females, with a median age of 61.5 years and range of 28-82 years), 16 with B-ALL (7 males and 9 females with a median age of 23.5 years and range of 1-72 years) and 20 with B-CLL (11 males and 9 females with a median age of 71.0 years and range of 42-93 years). Fourteen of the 19 AML patients were newly diagnosed patients; four patients represented a progression of refractory anemia with excess of blasts (RAEB) to AML with more than 20% blasts and one was a relapse. The latter Wve patients received neither chemo-nor radio-therapy at the time of blood collection for this study. However, two patients with a progression of RAEB to AML had received chemotherapy previously. All patients with B-ALL were newly diagnosed patients who had received no therapy. Blast counts in peripheral blood ranged from 9 to 96% (median 45%) in the AML patients and from 14 to 89% (median 53%) in the B-ALL patients. Finally, follow-up samples were taken from all B-CLL patients, except one; malignant B cells in peripheral blood ranged from 36 to 99% (median 81%).
Peripheral blood was also collected from 29 unrelated, randomly selected Belgian Caucasoids apparently healthy volunteers (HV) (9 males and 20 females, with a median age of 37.0 years and range of 22-54 years) after informed consent.
Peripheral blood mononuclear cells (PBMC) were isolated from citrate and EDTA peripheral blood by FicollHypaque density gradient centrifugation.
Cell lines
The AML ML2 cell line, the erythroleukemia K562 cell line, the monoblastic leukemia MONOMAC-6 cell line, and the T-ALL RPMI 8402 cell line were cultured in RPMI 1640 medium (Invitrogen Life technologies, Merelbeke, Belgium) supplemented with 1% L-glutamine (Invitrogen Life technologies), 1% penicillin-streptomycin (Invitrogen Life technologies) and 10% fetal calf serum (A&E ScientiWc, Marcq, Belgium).
Antibodies
The human mAb included the HLA-Cw1-speciWc mAb VP6G3 (an IgM) [20] ; the mAb WK4C11 (an IgM), which recognizes a determinant shared by HLA-Cw1, -Cw3, -Cw4, -Cw*0801, -Cw*1202 and -Cw*1402 alleles; the mAb TRA2G9 (an IgM), which recognizes a determinant shared by HLA-Cw1, -Cw3, -Cw4, and -Cw*1402 alleles [20] ; the mAb MUS4H4 (an IgG1), which recognizes a determinant shared by HLA-A24, -A25, -A32 and -HLABw4 alleles; the mAb VDK8F7 (an IgM), which recognizes a determinant shared by HLA-A23, A24 and HLA-Bw4 alleles, but not by B51, B53, B13, B63, and B49; the HLABw6-speciWc mAb OUW4F11 (an IgG1), and 30 allelespeciWc HLA mAbs. All these mAbs were developed and characterized by Dr. A. Mulder and most of them have been described elsewhere [16, 19, 20] . FITC-conjugated F(abЈ) 2 fragments of rabbit anti-human IgM and IgG antibodies were purchased from DakoCytomation (Heverlee, Belgium).
The mouse mAbs included the PE-anti-CD3 mAb SK7 (an IgG1), the PE-anti-CD19 mAb 4G7 (an IgG1), the PEanti-CD34 mAb 8G12 (an IgG1), the Cy5-anti-CD107a mAb H4A3 (an IgG1), and the PE-anti-CD56 mAb B159 (an IgG1) which were all purchased from BD Pharmingen, (Erembodegem, Belgium); the RPE-Cy5-anti-CD3 mAb S4.1 (an IgG2a), the PE-anti-CD45 mAb F10-89-4 (an IgG2a), and the anti-CD112 mAb R2.525 (an IgG1) which were all purchased from Serotec (Oxford, United Kingdom); the PE-anti-CD19 mAb B19 (an IgG2a), which was purchased from Chemicon (Heule, Belgium); the FITCanti-CD54 mAb 84H10 (an IgG1) and the FITC-anti-CD48 mAb J4-57 (an IgG1), which were both purchased from Beckman Coulter (Suarlée, Belgium); and the anti-CD155 mAb 300907 (an IgG1), the anti-MICA/B mAb 159207(an IgG2a), the anti-ULBP1 mAb 170818 (an IgG2a), the anti-ULBP2 mAb JQE01 (an IgG2a) and the anti-ULBP3 mAb JFY02 (an IgG2a), which were all purchased from R&D Systems (Abingdon, United Kingdom). FITC-conjugated F(abЈ) 2 fragments of goat anti-mouse IgG1 and IgG2a antibodies were purchased from ImTech Diagnostics (Antwerpen, Belgium).
Serologic HLA typing
The HLA-A, -B and -C phenotype was determined by testing PBMC with HLA typing trays (Biotest Seralc, Ternat, Belgium) in the complement dependent lymphocytotoxicity assay. This assay was performed by an experienced technician ensuring reproducibility and reliability of the results. In case of serological results compatible with HLA-A, -B or -C homozygosity of leukemic patients and HV, additional molecular typing was done utilizing a reverse hybridization technique (InnoLiPA, Innogenetics, Belgium) following the manufacturer's instructions.
Flow cytometry quantiWcation of HLA class I molecules Peripheral blood mononuclear cells were prestained for 20 min at room temperature with PE-or Cy5-conjugated anti-CD mAbs to distinguish normal T cells from leukemic cells in patients and from normal B cells in HV. Cell surface staining of cells was performed as described. BrieXy, unWxed cells (5 £ 10 5 ) were incubated for 25 min at room temperature with 25 l of a human mAb preparation (10 g/ml). Following two washings with phosphatebuVered saline (PBS) supplemented with an optimal amount of bovine serum albumin (BSA) (A&E ScientiWc, Marcq, Belgium), an optimal amount of FITC-anti-human IgM or IgG antibodies was added and incubation was continued for an additional 25 min at room temperature. Negative controls included samples incubated with an isotype-matched mAb recognizing a HLA class I allele not expressed on the sample being tested and cells incubated only with the secondary labeled mAb. Samples were analyzed with a Coulter Epics XL-MCL cytometer using the Coulter System II software v. 3.0. Cells were gated Wrst by forward versus sideward scatter. Then, leukemic B cells in patients with B-CLL were gated on high CD19 expression versus sideward scatter whereas the blasts in the AML patients were gated on high CD34 or on low CD45 expression versus side scatter. Leukemic blasts in B-ALL patients were gated on CD34 or on CD19 expression (CD34 negative) versus side scatter. The expression of HLA class I molecules by these leukemic cell populations was compared to that by autologous normal CD3 + T cells. In addition, PBMCs from 29 HV were also used to determine the range of expression of HLA class I molecules by normal CD19 + B and CD3 + T cells. The expression of the analyzed molecules was deWned by the mean Xuorescence intensity (MFI) and the cell surface antigen density was calculated by determining the MFI/mean forward scatter (MFSC) ratio. All values were corrected for cell size. In addition, the results were corrected with the background control values.
NK cell isolation NK cells were isolated by immunomagnetic depletion of T cells, B cells, dendritic cells, monocytes, granulocytes, platelets, and basophils from HV PBMCs using a cocktail of biotin-conjugated CD3, CD19, CD14, CD36 and antiIgE mAbs, and the NK cell Micro Bead Cocktail (Myltenyi Biotec, Utrecht, The Netherlands). Purity of NK cells ranged between 85 and 90%.
NK cell mediated cytotoxicity assay
This assay was performed as previously described [21] . BrieXy, cell lines and leukemic cells isolated from patients who had at least 85% leukemic cells in their peripheral blood were used as targets. The viability of target cells was assessed by trypan blue exclusion. HLA-Bw4 was masked by incubating target cells with the HLA-Bw4-speciWc mAb MUS4H4 (5 g/ml) (IgG1) for 20 min at 4°C. Cells incubated with an isotype-matched unrelated mAb under the same experimental conditions were used as speciWcity controls. To minimize the interference of antibody dependent cell mediated cytotoxicity (ADCC), NK cells were incubated with 50 l heat-inactivated serum from healthy AB + blood donors for 10 min at 4°C before the addition of target cells.
Target cells (1 £ 10 6 per ml) were prestained with 10 l lipophilic tracer 3,3Ј-dioctadecyloxacarbocyanine perchlorate (DIOC 18 at 3 mM, Invitrogen Life technologies) for 20 min at 37°C, washed and diluted to 1 £ 10 5 per ml. Subsequently, NK cells were added to 1 £ 10 4 target cells to yield an eVector (E):target (T) ratio of 10:1 in a Wnal volume of 200 l. After a 4-h incubation at 37°C in a 5% CO 2 atmosphere, cells were stained with propidium iodide (PI) (10 g/ml, Invitrogen Life technologies). A control sample with only target cells was included to monitor spontaneous cell death.
CD107a assay
The antitumor activity of NK cells was assessed by measuring the expression of the lysosome-associated membrane protein CD107a as a marker of degranulation. PuriWed NK cells were mixed at the eVector:target ratio of 1:2 with target cells (5 £ 10 4 ) in a 96-well microtiter plate in a total volume of 200 l of RPMI1640 medium. Following the addition of 5 l of a CD107a-speciWc cy5-mAb H4A3 preparation, the plate was incubated for 4 h at 37°C in a 5% The number of HLA class I alleles tested in each group depended on the availability of HLA class I allele-speciWc mAb with the appropriate speciWcity, the number of patients included, and the hetero-or homozygosity for the HLA class I locus tested (Fig. 1) . No signiWcant diVerences were found in the expression of the gene products of HLA-A, -B and -C loci between T cells from HV, and those from leukemic patients (data not shown). In addition in HV, the MFI values related to HLA class I alleles on B cells were generally higher than those on autologous T cells. As a result, the MFI ratios were greater than 1 (Fig. 1) . The MFI ratios related to HLA-A, -B, -C alleles in patients with AML, B-ALL and B-CLL were compared to those in HV. The MFI values related to HLA-A alleles on the leukemic blasts in patients with ALL and AML were mostly higher than those on the corresponding autologous T cells (Ratio > 1); the mean MFI ratio values were not diVerent from those in HV. It is noteworthy that in seven AML patients HLA-A alleles had a lower expression on blasts than on autologous T cells (Fig. 1a) . HLA-A antigen downregulation may provide myeloid blasts with a mechanism to escape from cytotoxic T lymphocyte (CTL) destruction; as a result, leukemic blast count may be increased. We therefore compared the percentage of leukemic blasts in patients with and without HLA-A antigen downregulation. The median blast count was 64.0% in the subgroup of seven AML patients with a MFI ratio lower than one and 41.5% in the remaining patients. However, this diVerence did not reach the level of statistical signiWcance (P = 0.181). In contrast, the expression of HLA-A alleles on B-CLL cells was downregulated in 15 patients. HLA-B alleles had a signiWcantly lower expression on the three types of leukemic cells than on B cells from HV (Fig. 1b) . In addition analysis of the expression of the HLABw4 and HLA-Bw6 group alleles showed that the MFI ratios related to HLA-Bw4 and HLA-Bw6 alleles on B-ALL cells are similar to those on B cells in HV (Fig. 1c, d) . In contrast, the expression of both HLA-Bw4 and HLA-Bw6 group alleles is signiWcantly lower on both B-CLL and AML cells than on B cells from HV (Fig. 1c, d) . The downregulation was especially marked for HLA-Bw6 group alleles on AML cells. It is noteworthy that the mean MFI ratio for HLA-Bw4 group alleles is greater than 1 on both B-CLL and AML cells. This result indicates that HLA-Bw4 and HLA-Bw6 group alleles are diVerentially expressed on B-CLL and AML cells and that HLA-HLA-Bw4 group alleles are not downregulated on 5 of the 11 B-CLL and 9 of the 16 AML cells.
To determine whether HLA class I alleles are diVerentially downregulated on leukemic cells, we compared the frequency of downregulation of some of the HLA-A and -B alleles tested in each leukemic patient group (Table 1) . This analysis could be performed only for the most frequent HLA-A and -B alleles since the number of samples available for the less frequent HLA-A and -B alleles and for HLA-C alleles was too low for such an analysis. The HLA-B44 allele had a signiWcantly (P < 0.01) higher frequency of downregulation than the other HLA class I alleles analyzed in AML patients. The HLA-B7 allele had also a higher frequency of downregulation than the HLA class I analyzed in AML patients. However, this diVerence did not reach the level of statistical signiWcance. In B-ALL the HLA-B5, -B8 and -B44 alleles had a higher frequency of downregulation than the other HLA class I alleles analyzed; however, none of the diVerences reached the level of statistical signiWcance. Last, all the HLA-A and -B alleles analyzed in B-CLL, with the exception of HLA-B7, were downregulated in at least 60% of the patients.
The analysis of HLA-C allele expression was restricted to HLA-Cw1, Cw3, Cw4, -Cw0801, -Cw1202, and -Cw1402 allospeciWcities; the expression of the other HLA-C allospeciWcities could not be analyzed because of the lack of mAb with the appropriate speciWcity. As a result, the expression of only 33.0% of the HLA-C alleles on leukemic cells could be analyzed. All of the tested HLA-C alleles were markedly downregulated on all three types of leukemic cells analyzed. Moreover, the mean values of the MFI ratios were all lower than 1, pointing out that HLA-C allele expression on nearly all leukemic cells was markedly lower than on their autologous normal T cells. Last, HLA-C alleles were barely detectable on leukemic blasts in four AML patients (Fig. 1e) .
In conclusion, the expression of one or more HLA class I alleles on leukemic cells, as determined by comparison with autologous T cells, was downregulated in 85.0, 62.5, and 68.4% of the B-CLL, B-ALL, and AML samples analyzed, respectively. In contrast, HLA class I allele loss on leukemic cells was not detected in this study.
The results of HLA class I typing obtained by Xow cytometric analysis of cells stained with HLA class I allele-speciWc human mAb were corroborated by those obtained by molecular typing and by testing with HLA typing trays in the CDC assay. It is of interest that in one B-CLL, one B-ALL, and six AML samples HLA class I alleles which were barely detectable on leukemic blasts by Xow cytometry were readily detectable by CDC.
Association of chromosomal abnormalities with HLA class I antigen downregulation
We tested whether HLA-A, -B, or -C allele downregulation was associated with molecular abnormalities (translocation, deletion, inversion and abnormal karyotype) in 15 of the 19 AML and 15 of the 16 B-ALL patients (Table 2 ). This analysis could not be performed in the group of B-CLL patients because most of them were not screened routinely for genetic aberrations.
The number of patients with molecular aberrations in the group of AML patients with a MFI ratio of HLA-A, -B, or -C alleles lower than one was not signiWcantly diVerent from that in the group of patients with a MFI ratio of at least one. It is of interest that the AML patient with chromosome 16 inversion showed the lowest HLA-A, -B, and -C allele expression level. All B-ALL patients (n = 5) with a MFI ratio lower than one for HLA-B alleles had an abnormal karyotype compared to 40% of the remaining patients (4/10). We did not measure the HLA-B expression of one B-ALL patient with an abnormal karyotype. In addition, three of these 5 B-ALL patients were positive for a translocation [t(9;22), t(5;10), or t (12;21) ]. In contrast, no association between molecular abnormalities and HLA-A or -C allele downregulation was found in B-ALL patients.
Impact of the HLA-Bw4 allele level on the susceptibility of leukemic cells to lysis mediated by allogeneic NK cell-mediated lysis To assess the functional relevance of the HLA class I allele expression level by leukemic cells, the insusceptibility to allogeneic NK cell-mediated lysis was investigated. B-CLL cells with a high HLA-Bw4 allele expression were used as targets in the CD107a and in the cytotoxicity assay (Fig. 2a, b) . Polyclonal NK cells from four donors who express KIR3DL1 and from two donors who do not express this inhibitory receptor were used as eVectors (Fig. 2a) . HLA typing of both NK cell donors and of the B-CLL patient ruled out NK cell alloreactivity triggered by a mismatch between inhibitory KIRs on donor NK cells and the HLA class I molecules on leukemic targets. Neither KIR3DL1 + nor KIR3DL1
¡ NK cells showed CD107 surface expression when they were incubated with B-CLL cells. Incubation of B-CLL cells with the HLA-Bw4-speciWc mAb MUS4H4 enhanced the percentage of CD107a positive NK cells in KIR3DL1 + donors, but had no marked eVect on the activation of NK cells in KIR3DL1 ¡ donors (Fig. 2a) . Furthermore, incubation of B-CLL cells with the HLABw6-speciWc mAb OUW4F11 had no detectable eVect on the CD107a expression on KIR3DL1 + and KIR3DL1 ¡ NK cells (Fig. 2a) . These Wndings were corroborated by the results of cytotoxicity assays performed in the presence of HLA-Bw4-speciWc mAb MUS4H4 to inhibit KIR3DL1-HLA-Bw4 allele interactions. NK cells from two KIR3DL1 + donors were used as eVectors. As shown in Fig. 2b , the HLA-Bw4-speciWc mAb MUS4H4 markedly enhanced the extent of lysis, while the HLA-Bw6-speciWc mAb OUW4F11 had no marked eVect. Moreover, the percentage of target cell lysis in the presence of HLA-Bw4-speciWc mAb correlated with the percentage of NK cells expressing KIR3DL1 (20.0% 3DL1 + NK clones in donor 1 vs. 11.8% 3DL1 + NK clones in donor 2). Unexpectedly, when B-CLL cells with HLA-HLA-Bw4 allele downregulation and B-ALL cells with a HLA-HLABw4 allele expression level within normal range were used as targets, the extent of lysis (Fig. 3b ) and the percentage of activated NK cells (Fig. 3a) from a 3DL1+ donor were very low. Whether the latter Wndings reXect the role of other resistance mechanisms to NK cell recognition could not be investigated, because leukemic cells from these patients were not available to perform these studies.
Therefore, the studies were continued with the cell lines K562, ML2, MONOMAC-6, and RPMI 8402. Polyclonal NK cells from two healthy donors were used as eVectors. Phenotyping of the two donors showed that both of them are heterozygous for HLA-Bw4 and HLA-Bw6 alleles and for group 1 and 2 of HLA-C ligands. HLA-Bw4 alleles are the ligands for the inhibitory 3DL1 receptor, while HLA-C alleles are the ligands for the inhibitory 2DL receptors. Moreover, both donors possessed all inhibitory KIR receptor genes, i.e., 2DL1, 2DL2, 2DL3, 3DL1, and 3DL2. To exclude the presence of the 3DL1*004 deletion variant, the expression of KIR3DL1 was conWrmed by Xow cytometry (data not shown). HLA class I phenotyping of the four cell lines by Xow cytometry showed that all of them with the exception of the K562 cells line, express the three major KIR ligands, i.e., HLA-Bw4, HLA-C1, and HLA-C2 alleles. In this way, we excluded donor NK cell alloreactivity caused by a mismatch between the inhibitory KIRs on donor NK cells and the HLA class I molecules on leukemic cell lines. Incubation of the four cell lines with increasing concentrations (0.5, 1, 5, 20 and 100 g/ml) of the HLABw4-speciWc mAb MUS4H4 caused a dose-dependent increase of the percentage of activated NK cells when they were incubated with the cell lines ML2 and MONOMAC (Fig. 4) .
The percentage of activated NK cells appears uniformly high when they were incubated with the K562 cell line and was not aVected by the incubation with the mAb MUS4H4 at all the concentrations tested. In contrast, no activation was detected when NK cells were incubated with the RPMI 8042 cell line (Fig. 4) . Additional experiments investigated whether the diVerential sensitivity of the four cell lines analyzed for NK cell recognition was caused by the diVerential expression of the ligands for the activating NK cell receptors. CytoXuorographic analysis of the cell lines stained with mAbs showed that PVR, Nectin-2 and the adhesion molecule ICAM-1 were expressed on K562, ML2, and MONOMAC-6 cells, but were not detectable on RPMI 8042 cells (data not shown). Furthermore the NKG2D ligands, MICA/B was weakly expressed only on K562 cells and ULBP-2 and -3 were expressed only on MONOMAC-6 cells (data not shown). Finally, CD48, the ligand for the 2B4 receptor was not detected on any of the cell lines. All together, these data show that all known ligands for the activating NK cell receptors were not detectable on the RPMI 8042 cell line. This phenotype may provide a mechanism for its lack of susceptibility to NK cell recognition.
Discussion
The scant information in the literature pertaining to the level of HLA class I alleles on leukemic cells and its potential role in the outcome of allogeneic HLA-mismatched HSCT to leukemic patients have prompted us to investigate this topic in B-ALL, AML, and B-CLL patients. Our study has shown that total HLA class I loss is rare, while selective HLA class I allele downregulation on leukemic cells occurs frequently and is most pronounced in B-CLL patients. From a methodological view point, two points are noteworthy. Defects in HLA class I allele expression could be identiWed in our study, since we utilized HLA class I allelespeciWc mAbs. This conclusion is in line with the evidence derived from studies of solid tumors that has shown that selective HLA class I allele downregulation cannot be detected by mAbs recognizing monomorphic determinats expressed on the gene products of HLA-A, -B, and -C loci [22, 23] . Furthermore, the complement dependent 
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cytotoxicity assay appears to be much more sensitive than Xow cytometric analysis in the analysis of HLA class I antigen expression by leukemic cells. This diVerence is likely to reXect the high sensitivity of leukemic cells to complement dependent lysis and/or the polyclonal nature of the HLA typing sera utilized in the complement dependent cytotoxicity assay. Our Wndings are in agreement with our previous data [16] , but are in apparent conXict with most of the results reported by Brouwer et al. [14] and Masuda et al. [17] , since both groups of investigators described a low frequency of HLA class I allele downregulation in the leukemic patient population analyzed. The apparent discrepancy between the results obtained by the latter two investigators and by ourselves is likely to reXect the diVerent criteria used to select the patient population to be included in the study and the HLA class I alleles included in the analysis. Brouwer et al. [14] who like us described a low frequency of total HLA class I loss in leukemic cells, utilized Xow cytometry to analyze only leukemic patients in whom single HLA class I allele loss had been detected by CDC assay; as a result, they could not detect HLA class I allele downregulation. Moreover, Masuda et al. [17] investigated only HLA-A allele expression mainly in AML patients and only in one B-CLL patient. In our study HLA-A allele expression was only signiWcantly downregulated in B-CLL patients.
The frequency of HLA-B allele downregulation which was high in patients with B-CLL and AML, was mostly restricted to those HLA-B allele with the HLA-Bw6 epitope. The data we have obtained about the expression of HLA-B alleles with the HLA-Bw4 epitope parallel, but are not superimposable onto those we previously described [16] SpeciWcally the frequency of HLA-Bw4 downregulation in the present study is higher than that in the previous one [16] . However, in both studies the level of HLA-Bw4 alleles is higher than that of HLA-Bw6 alleles; this diVerence may reXect the outgrowth of leukemic cells with high HLA-Bw4 allele expression because of the selective pressure imposed by NK cells on the leukemic cell population. In addition, we observed that the HLA-B7 and -B44 alleles were downregulated more frequently than others in AML patients. Although the number of AML patients analyzed for HLA-B7 and -B44 alleles is too low to draw deWnitive conclusions, it is intriguing that HLA-B44 has been reported to be lost more frequently than other HLA class I alles in solid tumors [24] ; whether this Wnding reXects the frequent use by malignant cells of HLA-B44 as a restricting element in their interactions with tumor antigen-speciWc CTL remains to be determined.
The analysis of HLA-C allele expression was limited to 33.0% of the known alleles because of the lack of mAb with the appropriate speciWcity. Nevertheless, our study has shown that HLA-C allele downregulation is frequent in all the three types of leukemic cells investigated and was most pronounced in the AML samples analyzed. Most AML cells showed a strong downregulation and in some cases even a complete loss of HLA-C alleles in comparison with their autologous T cells. This result might explain why donor NK cell alloreactivity based on HLA-C mismatch in AML patients does not always result in a markedly reduced incidence of relapse [9] [10] [11] , especially since Almeida and Davis [25] have recently showed that a high density of HLA-C proteins on target cells is required to inhibit NK cell cytotoxicity. In agreement with these results, our studies in progress suggest that HLA-C downregulation can indeed induce leukemic target lysis by allogeneic donor NK cells that are matched with a patient's KIR ligands (HLA-C and -Bw4). However, the functional signiWcance of this Wnding has to be interpreted with caution, because only a few NK cell cytotoxicity assays have been performed. Furthermore, no mAb that speciWcally blocks the HLA-C1 or -C2 epitopes was available to investigate the impact of HLA-C downregulation on NK cell activity.
What is the functional relevance of the defects in HLA class I allele expression we have found in leukemic cells? The "missing self" hypothesis would predict that leukemic cells with lost or downregulated HLA class I allele become susceptible to NK cell-mediated lysis [26] Our data show that HLA class I allele downregulation or loss on leukemic cell lines and B-CLL cells enhance NK cell activation and target cell lysis, provided that NK cell activating ligands are expressed by leukemic cells. These results parallel the susceptibility of melanoma cells with total HLA class I antigen loss to NK cell-mediated lysis only if NK cell activating ligands were expressed on melanoma cells [27] . Furthermore, NK cell-mediated lysis of B-ALL cells was not detected when HLA-Bw4 antigens were coated with mAb. This result may reXect the resistance of this leukemic cell type to NK cells because of the lack of expression of the LFA-1 adhesion molecule or other NK cell activating ligands [1, 28, 29] . A study reported by Pende et al. [30] and unpublished data from our laboratory found that the expression of diVerent NK cell activating ligands is variable among diVerent leukemic patients and therefore should be determined in order to deWne the susceptibility of leukemic cells to NK cell-mediated lysis. In addition, we cannot exclude that the resistance of leukemic cells to NK cellmediated lysis is caused by the expression of the non classical HLA class I antigen, HLA-G, although, to the best of our knowledge, this antigen has not been detected on leukemic cells [31, 32] .
Our study has clearly shown that besides the HLA and KIR genotype, expression levels of KIR ligands and of activating ligands on leukemic cells aVect their interactions with NK cells. If these in vitro data are paralleled by in vivo data, these variables should be taken into account in the selection of donor-recipient combinations for HSCT to leukemic patients. In addition, interpretation of the conXicting results pertaining to NK cell-mediated GvL eVects in related and unrelated allogeneic HSCT, which have been described in the literature, may beneWt from the inclusion of HLA class I allele expression and expression level of NK cell activating ligands on leukemic cells in the analysis of the data.
